The Top 3 Dividend Stocks to Buy Today

NASDAQ: AMGN | Amgen Inc. News, Ratings, and Charts

AMGN – Amid persistently high inflation, rising interest rates, and other macroeconomic headwinds, the stock market is expected to remain highly uncertain in the upcoming months. Therefore, it could be wise to invest in dividend-paying stocks Amgen (AMGN), Kimberly-Clark (KMB), and OneMain Holdings (OMF) to ensure a steady income stream. Keep reading….

A relatively resilient economy, along with stubbornly high inflation and weaker credit market conditions, lays out a difficult path ahead for the Fed. Amid an uncertain macro environment, investing in fundamentally sound, dividend-paying stocks Amgen Inc. (AMGN), Kimberly-Clark Corporation (KMB), and OneMain Holdings, Inc. (OMF) could be wise for stable returns.

Inflation remained stubbornly high in April. The Commerce Department reported that the core Personal Consumption Expenditures (PCE) price index rose 0.4% for the month, surpassing the 0.3% Dow Jones estimate.

On an annual basis, the gauge increased by 4.7%, exceeding expectations by 0.1 percentage point. The current levels remain significantly above the Federal Reserve’s 2% inflation target.

Despite the high-interest rate environment and elevated inflation, April’s spending figures reveal that consumers have persisted in their expenditures, mainly supported by a personal income increase. Consumer spending increased by 0.8%, while personal income accelerated by 0.4%.

Recent economic data showing persistent inflation alongside robust consumer spending could tempt the central bank to raise the federal funds rate further next month when a pause was on the table earlier.

Considering this macroeconomic backdrop, it could be wise to invest in dividend stocks as a defensive strategy for one’s portfolio. Therefore, fundamentally sound, dividend-paying stocks AMGN, KMB, and OMF could be ideal investments now.

Let’s take a closer look at the fundamentals of these stocks:

Amgen Inc. (AMGN)

AMGN develops, manufactures, and delivers human therapeutics, focusing on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience. Its products include Enbrel for plaque psoriasis, Neulasta to reduce infection risk in cancer patients with low white blood cell counts, and more.

On May 9, AMGN and TScan Therapeutics, Inc. joined forces to uncover antigens recognized by T cells in Crohn’s disease patients. Through TScan Therapeutics’ target discovery platform, AMGN is expected to gain access to a top-notch method for identifying new drug targets.

This collaboration has the potential to yield groundbreaking therapeutics, strengthening AMGN’s competitive advantage in meeting unmet medical needs.

AMGN has raised its dividends for 11 consecutive years. It pays an $8.52 per share dividend annually, which translates to a 3.93% yield on the current price level. Its dividend payments have grown at a 10.1% CAGR over the past three years, and its four-year average dividend yield is 2.91%.

For the first quarter that ended March 31, 2023, AMGN’s product sales increased 2% year-over-year to $5.85 billion. Its income before income taxes rose 105.5% year-over-year to $3.44 billion. Also, the company’s net income and EPS increased 92.5% and 97% from the year-ago values to $2.84 billion and $5.28, respectively.

The consensus revenue estimate of $28.14 billion for the fiscal year (ending December 2023) reflects a 6.9% year-over-year improvement. Likewise, the consensus EPS estimate of $18.21 for the current year indicates a 2.9% rise year-over-year.

Moreover, the stock surpassed the consensus revenue and EPS estimates in three of the trailing four quarters, which is impressive.

The stock marginally gained intraday to close the last trading session at $218.53.

AMGN’s strong fundamentals are apparent in its POWR Ratings. The stock has an overall rating of A, equating to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, each weighted to an optimal degree.

AMGN has an A grade for Quality and a B for Value and Stability. It is ranked #12 out of 378 stocks within the Biotech industry.

In addition to the POWR Ratings I’ve just highlighted, you can see AMGN’s ratings for Growth, Sentiment, and Momentum here.

Kimberly-Clark Corporation (KMB)

KMB manufactures and markets personal care and consumer tissue products globally. It operates through three segments, Personal Care; Consumer Tissue; and K-C Professional. The company sells household products directly to retail outlets as well as through distributors and e-commerce channels.

On April 20, KMB announced a regular quarterly dividend of $1.18 per share. The dividend will be paid on July 5, 2023, to shareholders recorded as of June 9, 2023.

KMB has a record of increasing dividends for 50 consecutive years. It pays a $4.72 per share dividend annually, translating to a 3.46% yield on the current share price. Its dividend payments have grown at a 3.9% CAGR over the past three years, and its four-year average dividend yield is 3.26%.

For the first quarter that ended March 31, 2023, KMB’s net sales increased 2% year over year to $5.20 billion, while its gross profit grew 13.6% year-over-year to $1.73 billion. The company’s net income came in at $575 million, up 7.5% from the year-ago value, and its EPS rose 7.7% year-over-year to $1.67.

Analysts expect KMB’s revenue to increase 2.4% year-over-year to $20.66 billion for the fiscal year ending December 2023. The company’s EPS for the ongoing year is expected to grow 11.1% year-over-year to $6.25. Also, the company surpassed its consensus revenue and EPS estimates in three of the trailing four quarters.

Shares of KMB have gained 8% over the past three months to close the last trading session at $133.57.

KMB’s robust outlook is apparent in its POWR Ratings. The stock has an overall rating of B, equating to Buy in our pro­­­­­­­­­prietary rating system.

KMB has a B grade for Quality, Stability, and Value. It has ranked #4 out of 51 stocks within the B-rated Consumer Goods industry.

Click here to access additional KMB ratings for Growth, Sentiment, and Momentum.

OneMain Holdings, Inc. (OMF)

OMF is a financial service holding company engaged in consumer finance and insurance business. It originates, underwrites, and services secured and unsecured personal loans; and offers credit cards and insurance products.

On May 2, OMF announced a partnership with FinMkt, a provider of embedded SaaS lending and payments solutions, to expand its presence in home improvement financing.

The collaboration would allow OMF to leverage FinMkt’s technology, resulting in a streamlined loan experience at the point of sale. With this partnership, the company could offer customers personalized credit solutions, enhancing its competitive edge and boosting its profitability and growth.

OMF pays a $4.00 per share dividend annually, translating to a 10.53% yield on the current price level. Its dividend payments have grown at a 53.4% CAGR over the past three years, and its four-year average dividend yield is 14.87%. The company has raised its dividends for three consecutive years.

For the fiscal first quarter that ended March 31, 2023, OMF’s other revenues grew 9.3% year-over-year to $177 million. As of March 31, 2023, the company’s total assets stood at $22.44 billion, compared to $21.82 billion as of March 31, 2022. Also, its cash inflows from operating activities increased by 1.8% year-over-year to $562 million.

The consensus revenue estimate of $4.42 billion for the fiscal year (ending December 2024) reflects a 3.9% year-over-year improvement. Likewise, the consensus EPS estimate of $7.65 for the same period indicates a 24.4% rise year-over-year. The stock has gained 16.6% year-to-date to close the last trading session at $38.57.

OMF’s solid fundamentals are apparent in its POWR Ratings. The stock has an overall rating of B, translating to Buy in our proprietary rating system.

OMF has a B grade for Growth and Quality. It is ranked #6 within the 48-stock Consumer Financial Services industry.

Click here to access additional OMF ratings (Value, Stability, Momentum, and Sentiment). 

The Bear Market is NOT Over…

That is why you need to discover this timely presentation with a trading plan and top picks from 40 year investment veteran Steve Reitmeister:

REVISED: 2023 Stock Market Outlook >


AMGN shares were trading at $220.01 per share on Wednesday afternoon, up $1.48 (+0.68%). Year-to-date, AMGN has declined -14.70%, versus a 9.40% rise in the benchmark S&P 500 index during the same period.


About the Author: Aanchal Sugandh


Aanchal's passion for financial markets drives her work as an investment analyst and journalist. She earned her bachelor's degree in finance and is pursuing the CFA program. She is proficient at assessing the long-term prospects of stocks with her fundamental analysis skills. Her goal is to help investors build portfolios with sustainable returns. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
AMGNGet RatingGet RatingGet Rating
KMBGet RatingGet RatingGet Rating
OMFGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Why Its Time to Buy Small Cap Stocks

The S&P 500 (SPY) is making new record highs, but oddly small caps are heading lower in October. Why is that? And why does 44 year investment veteran say that now is the perfect time to buy up small caps for a big rally ahead? Read on for more...

3 Biotech Stocks With Huge Upside Based on Analyst Price Targets

The biotech sector’s long-term growth is fueled by strong government support, increasing funding and M&A activities, and rapid AI adoption. Therefore, quality biotech stocks Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), and Biogen (BIIB) with major upside could be ideal additions to your portfolio. Keep reading...

3 Tech Stocks Under $55 That Analysts Love

The technology industry is experiencing unprecedented expansion owing to the growing demand for generative AI, IT investment, and government support. Thus, it could be wise to invest in fundamentally sound tech stocks such as Pure Storage (PSTG), Flex (FLEX), and Informatica (INFA), which are currently trading under $55. Read on...

3 Consumer Discretionary Stocks to Watch for Holiday Gains

The consumer discretionary sector is poised for significant growth, driven by changing consumer behaviors, rising incomes, and increasing demands for entertainment, apparel, and leisure, particularly during the holiday season. Therefore, investors could consider watching consumer discretionary stocks: Amazon.com (AMZN), The Home Depot (HD), and Target (TGT) for potential holiday gains. Keep reading...

October Stock Market: More Trick Than Treat?

The S&P 500 (SPY) has been in the plus column for 5 straight months. Investment pro Steve Reitmeister shares why that party ends in October and how to prepare for resumption of the bull market in November and beyond. Read below for full story...

Read More Stories

More Amgen Inc. (AMGN) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All AMGN News